These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23820942)

  • 1. Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome.
    Middeke JM; Bruck N; Parmentier S; Bornhäuser M; Schetelig J
    Ann Hematol; 2014 Mar; 93(3):531-2. PubMed ID: 23820942
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
    Ribeiro RC; Pui CH
    Clin Lymphoma; 2003 Mar; 3(4):225-32. PubMed ID: 12672271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?
    Zaidi SZ; Aljurf M
    J Clin Oncol; 2004 Aug; 22(16):3430-1; author reply 3431-2. PubMed ID: 15310789
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
    J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of impending tumor lysis with single-dose rasburicase.
    Lee AC; Li CH; So KT; Chan R
    Ann Pharmacother; 2003 Nov; 37(11):1614-7. PubMed ID: 14565793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
    Bose P; Qubaiah O
    J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
    Pession A; Barbieri E; Santoro N; Paolucci P; Porta F; Locatelli F
    Haematologica; 2005 Jan; 90(1):141-2. PubMed ID: 15642687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
    Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
    Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case report of fatal tumor lysis syndrome after chemotherapy in a pregnant patient with Burkitt's lymphoma.
    Serikawa T; Abe T; Minamikawa T; Itsukaichi M; Yamada K; Saito T; Kaneko T; Wada M; Takakuwa K; Tanaka K
    J Obstet Gynaecol Res; 2011 Aug; 37(8):1141-4. PubMed ID: 21481095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
    Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
    Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis.
    Macfarlane RJ; McCully BJ; Fernandez CV
    Pediatr Nephrol; 2004 Aug; 19(8):924-7. PubMed ID: 15179573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour lysis syndrome in children: experience of last decade.
    Ahn YH; Kang HJ; Shin HY; Ahn HS; Choi Y; Kang HG
    Hematol Oncol; 2011 Dec; 29(4):196-201. PubMed ID: 21710502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
    Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
    Wössmann W; Schrappe M; Meyer U; Zimmermann M; Reiter A
    Ann Hematol; 2003 Mar; 82(3):160-5. PubMed ID: 12634948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW; Lo M; Crank CW
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor lysis syndrome, case report and review of the literature.
    Masera G; Jankovic M
    Ann Oncol; 1997 Jan; 8(1):97. PubMed ID: 9093714
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?
    Agrawal AK; Feusner JH
    Br J Haematol; 2011 Apr; 153(2):275-7. PubMed ID: 21255003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.